Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00445003 · ClinicalTrials.gov registry record · Phase 3
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
A Phase 3 study, sponsored by Jaeb Center for Health Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 333
- Enrollment target
NCT00445003: Completed Phase 3 study, sponsored by Jaeb Center for Health Research.
NCT00445003 is a Phase 3 study that has completed, run by Jaeb Center for Health Research. The registered enrollment target is 333 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (57% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00445003, a Phase 3 study, has completed, sponsored by Jaeb Center for Health Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 333 participants
- Enrollment target
Study Summary
The purpose of the study is to find out if treatment with an intravitreal injection of triamcinolone or an intravitreal injection of ranibizumab can prevent loss of vision caused by panretinal photocoagulation treatment. At the present time, it is not known whether intravitreal steroid or anti-vascular endothelial growth factor (anti-VEGF) injections are beneficial in preventing vision loss after panretinal photocoagulation (PRP) treatment. It is possible that one or both of the types of injections will prevent vision loss after PRP treatment. However, it is not known whether the benefits of the injections will outweigh the risks. It is possible that because of side effects, the injections may not be as good as laser alone in treating the diabetic retinopathy.
Primary Outcome
Visual Acuity was measured with the Electronic Early Treatment Study (E-ETDRS) visual acuity test. Unit of measure is based on the E-ETDRS letter score scale, 0-97, where 0 = worst and 97 = best.
Interventions
- DRUG Triamcinolone Acetonide
- DRUG Ranibizumab
- BEHAVIORAL Sham injection
- PROCEDURE Focal/grid laser
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 333 participants |
| Start Date | 2007-03 |
| Est. Completion | 2010-07 |
| Phase | Phase 3 |
What the finished NCT00445003 record still lists
NCT00445003 is an interventional study that assigns participants to a tested intervention. The registered 333 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (57% lower).
The record links to 0 conditions, and to 4 interventions - of which Triamcinolone Acetonide is the first listed.
NCT00445003 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00445003 about?
NCT00445003 is a clinical study titled "Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy". The purpose of the study is to find out if treatment with an intravitreal injection of triamcinolone or an intravitreal injection of ranibizumab can prevent loss of vision caused by panretinal photocoagulation treatment. At the present time, it is not known whether intravitreal steroid or anti-vascu...
What is the current status of trial NCT00445003?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 333 participants. The study started on 2007-03. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00445003?
The interventions under investigation include: Triamcinolone Acetonide (DRUG), Ranibizumab (DRUG), Sham injection (BEHAVIORAL), Focal/grid laser (PROCEDURE).
Who is sponsoring clinical trial NCT00445003?
This trial is sponsored by Jaeb Center for Health Research, which has 119 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00445003's enrollment target sits among peer trials
333 1061st of 2000 higher than 940 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07395687 · 333 participants · Phase 2
A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity
- NCT05131672 · 334 participants · NA
Cast or Operation for Medial Epicondyle Fracture Treatment in Children
- NCT05131685 · 334 participants · NA
Distal Radius Interventions for Fracture Treatment
- NCT05546931 · 334 participants · NA
Mobile Health Program for Rural Hypertension
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia